DNA Print Genomics Inc DNAG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- — / —
- Market Cap
- $644.61
- Volume/Avg
- 269,000 / 185,315
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
DNA Print Genomics Inc is a pharmaceutical company that focuses on the human genome sciences. Through its subsidiaries, it is into research and development of genomic products and provides scientific services and tests to the genealogy, forensic, pharmaceutical, and genetics markets; and focuses on personalized medicine; and other operations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 25
- Website
- —
Valuation
|
Metric
|
DNAG
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DNAG
|
|---|---|
Quick Ratio | 0.14 |
Current Ratio | 0.17 |
Interest Coverage | — |
Quick Ratio
No chart available
Profitability
|
Metric
|
DNAG
|
|---|---|
Return on Assets (Normalized) | −77.40% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −13,021.99% |
Return on Assets
No chart available
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Whqgqrdvm | Zypq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jhqrcfy | Sbvvcxh | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mpbnhxhp | Jrmbnz | $97.8 Bil | |
MRNA
| Moderna Inc | Cgpxxqd | Bvw | $41.3 Bil | |
ARGX
| argenx SE ADR | Lktlfgsg | Fkjg | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Rjkkrdsd | Zbspd | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gwcrjlqx | Wkkvtwn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Skcgnzrt | Lnldyz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rvsmkbclm | Cfwckr | $12.5 Bil | |
INCY
| Incyte Corp | Zrwqxtrj | Hnspdvc | $11.6 Bil |